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Cortical cholinergic deficiency is prominent in Alzheimer’s disease (AD), and published findings of diminished pupil flash response
in AD suggest that this deficiency may extend to the visual cortical areas and anterior eye. Pupillometry is a low-cost, noninvasive
technique that may be useful for monitoring cholinergic deficits which generally lead to memory and cognitive disorders. The aim
of the study was to evaluate pupillometry for early detection of AD by comparing the pupil flash response (PFR) in AD (N = 14) and
cognitively normal healthy control (HC, N = 115) participants, with the HC group stratified according to high (N = 38) and low
(N = 77) neocortical amyloid burden (NAB). Constriction phase PFR parameters were significantly reduced in AD compared to
HC (maximum acceleration p < 0 05, maximum velocity p < 0 0005, average velocity p < 0 005, and constriction amplitude
p < 0 00005). The high-NAB HC subgroup had reduced PFR response cross-sectionally, and also a greater decline
longitudinally, compared to the low-NAB subgroup, suggesting changes to pupil response in preclinical AD. The results
suggest that PFR changes may occur in the preclinical phase of AD. Hence, pupillometry has a potential as an adjunct for
noninvasive, cost-effective screening for preclinical AD.
1. Introduction
The ocular pupil controls retinal illumination and responds
dynamically to a bright flash of light by rapid constriction
followed by redilation (Figure 1). Pupillometry investigates
this responsebydelivering aflashof light into the eye andaccu-
rately detecting and measuring pupil size changes over time.
Pupil size and response are controlled by the opposing
action of the sphincter and dilator muscles of the iris. The
constriction phase of the pupil response (Figure 1) is primar-
ily driven by the cholinergic system [1], with acetylcholine
(ACh) being the neurotransmitter involved in projections
between the Edinger-Westphal nucleus, ciliary ganglion,
and sphincter muscle [2]. Thus, pupillometry provides a
practical, noninvasive approach with which to evaluate
cholinergic deficiency.
Pupillometry has been used to identify a cholinergic
deficiency in a number of disorders including Alzheimer’s
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disease (AD) [3–8] and Parkinson’s disease [5, 9]. As the
primary neurotransmitter deficit in AD is ACh [10–12], the
constriction phase of the pupil flash response (PFR) has
gained interest for evaluating cholinergic deficiency and for
early detection, diagnosis, and monitoring of AD. The major-
ity of study results to date indicate a slower and reduced pupil
response in AD, with reduced velocities, accelerations, and
constriction amplitude, and increased latencies. The work
of Ferrario et al. [6] on only constriction acceleration stands
in contrast, possibly due to different methodology and partic-
ipant selection. Some studies indicate a faster recovery after
stimulus in AD, despite slower constriction and dilation
velocities, probably due to the reduced amplitude [3, 13].
Our prior study [8] found a weaker pupil constriction
response in AD, consistent with the hypothesis of a choliner-
gic deficit in the peripheral parasympathetic pathway in AD.
Significant differences were found between AD and cogni-
tively normal healthy control (HC) participants in 10 differ-
ent calculated PFR parameters, with the greatest differences
coming from the constriction phase: maximum constriction
acceleration, maximum constriction velocity, mean constric-
tion velocity, and constriction amplitude. These promising
preliminary results warranted further investigation into
whether pupil response changes occur early in AD, possi-
bly providing a test for early detection or monitoring of
the disease.
AD is characterized clinically by a progressive decline
in memory, learning, and executive function and
neuropathologically by the presence of cerebral extracellular
amyloid deposits (plaques), intracellular neurofibrillary
tangles, and cerebral (in particular hippocampal) atrophy.
In addition to the debilitating symptoms endured by AD
patients, the disease imposes a huge social and economic
burden on society [14].
AD cognitive symptoms arise only after extensive, irre-
versible neural deterioration has already occurred. As a
result, diagnosis is usually made late in the disease process,
limiting both the efficacy of available treatments and the
evaluation of new treatments. Biomarkers for early detec-
tion of AD include cerebrospinal fluid concentrations of
beta-amyloid (Aβ), total tau and phosphorylated tau pep-
tides [15–18], and brain Aβ plaque burden imaged using
positron emission tomography (PET) [16, 18–20]. Research
demonstrates that plaque burden can be detected over 20
years before cognitive symptoms begin [21]. However, while
these are valuable diagnostic and secondary screening bio-
markers, they are not suitable as primary screening technol-
ogies for AD. A screening process that could provide early,
accurate diagnosis or a prognosis of AD would enable
earlier intervention, facilitate cost-effective screening into
treatment trials, and allow current and future treatments
to be more effective.
The present study investigated constriction phase pupil
response in AD and HC participants, with a particular focus
on PFR changes in preclinical AD as determined by high
neocortical amyloid burden (NAB).
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Figure 1: Illustration of pupil flash response and parameters measured. (a) Pupil diameter over time after stimulus at time zero. (b) Pupil
velocity (rate of change of pupil diameter). (c) Pupil acceleration (rate of change of velocity). The constriction phase lasts from stimulus to
minimum pupil size; parameters calculated during this phase are the constriction amplitude, maximum and average constriction velocity,
and maximum constriction acceleration.
2 Journal of Ophthalmology
2. Materials and Methods
2.1. Participants. Participants for the study were recruited
from the Australian Imaging, Biomarkers, and Lifestyle
(AIBL) study of ageing in Australia. The AIBL study has
two sites: Melbourne (Victoria) and Perth (Western
Australia). The pupillometry study was conducted only at
the Perth site. A previous report details the AIBL study
design and baseline cohort [22]. Briefly, the AIBL study inte-
grates data from neuroimaging, biomarkers, lifestyle, clinical,
and neuropsychological domains for eligible volunteers older
than 60 years who are fluent in English. AIBL classifies par-
ticipants into 3 groups: (1) individuals meeting the criteria
for AD based on the NINCDS-ADRDA (National Institute
of Neurological and Communicative Disorders and Stroke-
Alzheimer’s Disease and Related Disorders Association)
[23], (2) individuals meeting the criteria for mild cognitive
impairment [24, 25], and (3) cognitively normal healthy
control individuals.
The following were part of the AIBL exclusion criteria: a
history of non-AD dementia, schizophrenia, bipolar disor-
der, significant current (but not past) depression (geriatric
depression scale above 5/15), Parkinson’s disease, cancer
(other than basal cell skin carcinoma) within the last 2
years, symptomatic stroke, uncontrolled diabetes, diagnosed
obstructive sleep apnoea, or current regular alcohol use
exceeding 2 standard drinks per day for women or 4 per
day for men.
AIBL participants were excluded from the pupil response
study if they did not have PET data available; if they had
pupillary malformations, severe cataract, self-reported his-
tory of glaucoma in either eye, penetrating eye wounds to
both eyes, and eye surgery to both eyes that involved the
muscle; if they used cholinesterase inhibitors or prescribed
ocular medications; or if they were unable to complete the
task without excessive blinking.
All participants provided written informed consent, and
all PFR procedures were approved by the Hollywood
Private Hospital Research Ethics Committee according to
the Helsinki Declaration. Approval for the parent AIBL study
was obtained from the Austin Health Human Research
Ethics Committee, the Hollywood Private Hospital Research
Ethics Committee, the St. Vincent Hospital Research
Ethics Committee, and the Edith Cowan University Human
Research Ethics Committee.
The present study draws upon data generated from the
AIBL study, including neuroimaging and genetic test results.
The methodology for these AIBL procedures is reported
elsewhere [22] and summarized below.
2.2. Neuroimaging. Neuroimaging methodology is reported
in more detail elsewhere [26]. Briefly, participants were
neuroimaged for the presence of fibrillar brain Aβ using
PET with 2 different radiotracers: 11C-Pittsburgh compound
B (PiB) and 18F-flutemetamol (FLUTE). Previous reports
describe the PET methodology for each tracer in detail
[20, 27]. For semiquantitative analysis, a volume of interest
template was applied to the summed and spatially normal-
ized PET images to obtain a standardized uptake value
(SUV). The images were then scaled to the SUV of each
tracer’s recommended reference region to generate a tissue
ratio termed SUV ratio (SUVR). A global measure of NAB
was computed using the mean SUVR in the frontal, superior
parietal, lateral temporal, occipital, and anterior and poste-
rior cingulate regions of the brain. For PiB, the SUV was nor-
malized to the cerebellar cortex, whereas the pons was used as
the reference region for FLUTE [28]. SUVR was stratified
into a dichotomous variable classified as high or low based
on neuropathologically validated thresholds for each tracer.
We considered participants who underwent FLUTE imaging
to have high NAB when the SUVR was 0.62 or higher [28],
and for PiB imaging, when the SUVR was 1.4 or higher [29].
2.3. Genotyping. APOE genotyping was performed according
to the following protocol: fasting blood samples were
obtained using standard venepuncture of the antecubital vein
and collected into EDTA tubes containing prostaglandin E1
(PGE: 33.3 ng/ml; Sapphire Bioscience, NSW, Australia) to
prevent platelet activation. Extraction of DNA from 5ml of
whole blood was undertaken using QIAamp DNA Blood
Maxi Kits (Qiagen, Hilden, Germany) as per the manufac-
turer’s instructions. Specific TaqMan® (Thermo Fisher
Scientific, Waltham, MA, USA) genotyping assays were
used for ascertaining APOE genotype (rs7412, assay ID:
C____904973_10; rs429358, assay ID: C___3084793_20),
which were performed on a QuantStudio 12K Flex™
real-time PCR system (Thermo Fisher Scientific, Waltham,
MA, USA) using the TaqMan GTXpress™ Master Mix
(Thermo Fisher Scientific, Waltham, MA, USA).
2.4. System of Pupillometry. A record of the pupil’s response
to a flash of light was collected for each participant using a
commercial pupillometer. The PFR was collected using a
NeurOptics™ VIP™-200 Pupillometer. This is a commercial,
monocular device providing fully automated operation and
calculation of response parameters. The device produces a
white flash stimulus and then measures the pupil size for
5 seconds using infrared illumination. The video frame
rate is 33Hz, the stimulus/pulse intensity is 180μW, and
the stimulus/pulse duration is 31ms. The pupillometer
produces diffuse light over the whole visual field.
The room was darkened for 2 minutes prior to testing.
The test was practiced once before recording. Occasionally,
an extra trial was needed to achieve a recording without
blinks or artefacts. Data was rejected if artefacts were present.
The right eye was used for all participants, except where there
was injury or pathology to the right eye only or a suitable
pupil response could not be obtained with the right eye, in
which case the left eye was used (N = 1). The pupillometer
provided automatic calculation of the following pupil
response parameters: resting pupil diameter (D1, mm), min-
imum pupil diameter (D2, mm), average constriction veloc-
ity (CV, mm/sec), maximum constriction velocity (MCV,
mm/sec), and constriction amplitude (AMP, mm), which
was calculated as the difference between resting pupil diame-
ter and minimum pupil diameter (D1−D2, mm). A record of
the pupil’s diameter as a function of time was exported from
the pupillometer. From this record, maximum constriction
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acceleration (MCA, mm/sec2) was calculated by masked
operators using fully automated computer algorithms. PFR
trials with artefacts or excessive blinking were discarded. A
computer algorithm was used to remove minor blinks.
2.5. Statistical Analysis. Descriptive statistics including
means and standard deviations (SD) for the full cohort and
clinical group are shown in Table 1. Demographic compari-
sons were performed using a χ2 test (Fisher’s exact calcula-
tion where necessary) for categorical variables (gender and
APOE ε4 status), and analysis of variance (ANOVA) for the
continuous age variable (p < 0 05 considered significant).
Pupil response measures were compared between groups
using generalised linear modelling, with confounding vari-
ables reduced via the stepAIC method (a stepwise model
selection by Akaike information criterion). Confounders
considered included age, sex, and APOE ε4 status (the major
genetic risk factor for sporadic AD [30]). Statistical signifi-
cance was defined as p < 0 05. All statistical analyses were
conducted in the R statistical environment [31]. The likeli-
hood of false-positive results was minimised by comparing
p values to adjusted critical values according to the Benjamini
and Hochberg false discovery rate (FDR) method [32].
Receiver-operating characteristic (ROC) curve analysis was
also performed to further illustrate the classification accu-
racy of the PFR parameters. The area under the curve
(AUC) of the ROC curves was estimated, an AUC of 1
indicates perfect classification ability, whereas an AUC near
0.5 indicates poor (random) classification ability. Logistical
models combining PFR measures were created to assess
combined classification performance.
3. Results
Eligible AIBL participants in Perth with PET data available
numbered 206 (182 HC, 24 AD). N = 180 (87%) were willing
to participate in the pupillometry study. Participants were
excluded from the pupil response study if they had pupillary
malformations, severe cataract (N = 5), self-reported history
of glaucoma in either eye, penetrating eye wounds to both
eyes, and eye surgery to both eyes that involved the muscle;
if they used cholinesterase inhibitors or prescribed ocular
medications (N = 36); or if they were unable to complete
the task without excessive blinking (N = 10). All participants
were white Caucasians.
The pupillometry study thus included N = 129 partici-
pants (115 HC, 14 AD). Table 1 shows the demographic
comparisons between HC and AD groups, Table 2 shows
the same for the HC group stratified according to NAB
status, and Table 3 shows the same for the 37 HC participants
with longitudinal pupillometry results available, again strati-
fied according to NAB status.
There was a significantly greater proportion of APOE ε4
carriers in the AD group (Table 1, p = 0 000001), consistent
with APOE ε4 being the major genetic risk factor for sporadic
AD. The AD group was also older (mean age 77.4 years)
compared to the HC group (mean age 72.9 years) (p = 0 002).
PFR parameters were not significantly different between
males and females, or between APOE ε4 carriers and noncar-
riers, but they did exhibit an age dependence (MCV
p = 0 00002, CV p = 0 00001, MCA p = 0 002, and AMP
p = 0 02).
Significant differences in pupil response were found
between the AD and HC groups (Table 1). Specifically, the
AD group exhibited reduced MCV (p = 0 00045, Figure 2),
AMP (p = 0 0030), MCA (p = 0 030), and CV (p = 0 0015).
All results were significant after adjustment using the
Benjamini and Hochberg FDR method [32].
MCV provided the greatest clinical classification accu-
racy with sensitivity 100%, specificity 67%, and AUC 0.85
(CI [0.76–0.93]). Combining PFR parameters into a logistic
model did not improve classification performance, as the
parameters were highly correlated. However, adding age
and APOE є4 carrier status improved classification perfor-
mance to sensitivity 91.7%, specificity 93.1%, and AUC 0.94
(CI [0.87–1]).
Stratifying the HC group according to NAB, the low-
NAB group consisted of 77 participants of mean age 72.3
years, while the high-NAB group consisted of 38 participants
of mean age 74.0 years. Demographics and results of this
Table 1: Demographics and descriptive PFR analysis for HC and AD groups, with ANOVA, χ2 test, and GLM analysis.
Healthy control Alzheimer’s disease p value
Number of participants [N] 115 14
Age: years [mean (±SD)] 72.9 (±5.3) 77.4 (±5.4) 0.002~
Sex: male [N (%)] 56 (49) 10 (61) 0.11†
APOE ε4 carrier [N (%)] 27 (23) 12 (86) 0.000001†
MCA [mm/sec2, mean (±SD)] 31.12 (±6.56) 26.84 (±4.23) 0.030‡
MCV [mm/sec, mean (±SD)] 4.22 (±0.65) 3.41 (±0.55) 0.00045‡
CV [mm/sec, mean (±SD)] 3.02 (±0.49) 2.53 (±0.44) 0.0015‡
AMP [mm, mean (±SD)] 1.46 (±0.28) 1.15 (±0.28) 0.0030‡
~Analysis of variance (ANOVA) for the continuous age demographic variable (p < 0 05 considered significant). †χ2 test for categorical demographic variables
(gender and APOE ε4 carrier status) (p < 0 05 considered significant). ‡p value from generalised linear model analysis of differences between groups (including
significant confounders). Bold values significant after adjustment for false discovery rate (FDR) using the Benjamini and Hochberg method. APOE ε4 carrier
status refers to carrier/noncarrier of an apolipoprotein E ε4 allele. SD refers to standard deviation, mm refers to millimetres, sec refers to seconds, PFR refers to
pupil flash response, HC refers to healthy control, AD refers to Alzheimer’s disease, GLM refers to generalised linear methods, MCA refers to maximum
constriction acceleration, MCV refers to maximum constriction velocity, CV refers to average constriction velocity, and AMP refers to constriction amplitude.
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comparison are presented in Table 2. There was a signifi-
cantly greater proportion of APOE ε4 carriers in the high-
NAB group (p = 0 0002), again consistent with APOE ε4
being the major genetic risk factor for sporadic AD. MCV
was reduced in the high-NAB group (p = 0 021). The remain-
ing PFR parameters exhibited nonsignificant trends for
reduced values in the high-NAB group. Combining MCV
and MCA into a logistic model provided classification accu-
racy for high NAB with sensitivity 57.1%, specificity 71.6%,
and AUC 0.63 (CI [0.52–0.75]). Adding age and APOE ε4
carrier status improved the performance of the model to sen-
sitivity 60%, specificity 88%, and AUC 0.74 (CI [0.63–0.84]).
Thirty HC participants (19 low NAB, 11 high NAB)
underwent longitudinal pupillometry, with PFR data col-
lected using the same device and an intermeasurement
period ranging 27–36 months prior to this study [8]. The
change in PFR parameters between visits was calculated.
Demographics and results of this comparison are pre-
sented in Table 3. There was again a significantly greater
proportion of APOE ε4 carriers in the high-NAB group
(p = 0 035). The high-NAB group also had a greater per-
centage of males (73%) compared to the low-NAB group
(37%) (p = 0 00026). PFR parameters were not signifi-
cantly correlated with the exact interval between longitu-
dinal measurements.
Group means for each PFR parameter change were
negative, indicating a weaker PFR at the more recent pupillo-
metry test. The reduction in MCA and MCV was more
pronounced in the high-NAB group (p = 0 0068, p = 0 047,
resp.). The MCA result was still significant after Benjamini
and Hochberg FDR adjustment [32]; however, the maxi-
mum velocity result was not. Combining MCA and MCV
in a logistic model provided a classification accuracy for high
NAB with sensitivity 73%, specificity 100%, and AUC 0.90
Table 2: Demographics and descriptive PFR analysis for the HC group stratified according to neocortical amyloid burden (NAB), with
ANOVA, χ2 test, and GLM analysis.
Healthy control [low NAB] Healthy control [high NAB] p value
Number of participants [N] 77 38
Age: years [mean (±SD)] 72.3 (±5.2) 74.0 (±5.3) 0.05734~
Sex: male [N (%)] 35 (49) 20 (53) 0.433†
APOE ε4 carrier: [N (%)] 10 (13) 17 (45) 0.000202†
MCA [mm/sec2, mean (±SD)] 32.97 (±5.96) 30.08 (±7.2) 0.067‡
MCV [mm/sec, mean (±SD)] 4.48 (±0.63) 4.05 (±0.62) 0.021‡
CV [mm/sec, mean (±SD)] 3.23 (±0.47) 2.92 (±0.42) 0.12‡
AMP [mean (±SD)] 1.54 (±0.29) 1.41 (±0.26) 0.77‡
~Analysis of variance (ANOVA) for the continuous age demographic variable (p < 0 05 considered significant). †χ2 test for categorical demographic variables
(gender and APOE ε4 carrier status) (p < 0 05 considered significant). ‡p value from the generalised linear model analysis of differences between groups
(including significant confounders). Bold values significant after adjustment for false discovery rate (FDR) using the Benjamini and Hochberg method.
APOE ε4 carrier status refers to carrier/noncarrier of an apolipoprotein E ε4 allele. NAB refers to neocortical amyloid burden, SD refers to standard
deviation, mm refers to millimetres, sec refers to seconds, PFR refers to pupil flash response, HC refers to healthy control, AD refers to Alzheimer’s disease,
GLM refers to generalised linear methods, MCA refers to maximum constriction acceleration, MCV refers to maximum constriction velocity, CV refers to
average constriction velocity, and AMP refers to constriction amplitude.
Table 3: Demographics and descriptive PFR analysis for the longitudinal HC group stratified according to neocortical amyloid burden
(NAB), with ANOVA, χ2 test, and GLM and ROC analyses.
Healthy control [low NAB] Healthy control [high NAB] p value
Number of participants [N] 19 11
Age: years [mean (±SD)] 72.2 (±0.31) 72.1 (±4.3) 0.97~
Sex: male [N (%)] 7 (37) 8 (73) 0.00026†
APOE ε4 carrier [N (%)] 4 (21) 10 (91) 0.035†
Change in MCA [mm/sec2, mean (±SD)] −1.49 (±1.80) −5.66 (±3.10) 0.0068‡
Change in MCV [mm/sec, mean (±SD)] −0.19 (±0.17) −0.55 (±0.42) 0.047‡
Change in CV [mm/sec, mean (±SD)] −0.52 (±0.75) −0.21 (±0.1) 0.62‡
Change in AMP [mm, mean (±SD)] −0.24 (±0.32) −0.13 (±0.09) 0.24‡
~Analysis of variance (ANOVA) for the continuous age demographic variable (p < 0 05 considered significant). †χ2 test for categorical demographic variables
(gender and APOE ε4 carrier status) (p < 0 05 considered significant). ‡p value from the generalised linear model analysis of differences between groups
(including significant confounders). Bold values significant after adjustment for false discovery rate (FDR) using the Benjamini and Hochberg method.
APOE ε4 carrier status refers to carrier/noncarrier of an apolipoprotein E ε4 allele. NAB refers to neocortical amyloid burden, SD refers to standard
deviation, mm refers to millimetres, sec refers to seconds, PFR refers to pupil flash response, HC refers to healthy control, AD refers to Alzheimer’s disease,
GLM refers to generalised linear methods, MCA refers to maximum constriction acceleration, MCV refers to maximum constriction velocity, CV refers to
average constriction velocity, and AMP refers to constriction amplitude.
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(CI [0.75–1]). Adding age and APOE ε4 carrier status
improved the performance of the model to sensitivity 91%,
specificity 100%, and AUC 0.99 (CI [0.96–1.0]).
4. Discussion
The results are indicative of a weaker constriction phase pupil
response in AD, consistent with earlier studies [3–5, 9].
Possible causes of the PFR changes in AD are degeneration
in relays in the midbrain or central cholinergic depletion
[11, 12]. The four PFR parameters considered in this study
are all measures of the constriction phase of the PFR which
is primarily a parasympathetic cholinergic response [1].
These four PFR parameters were also the same parameters
that were most significantly altered in AD in prior studies
[3–8]. The results therefore suggest cholinergic deficits in
the peripheral parasympathetic pathway in AD. AD
patients receiving pharmacological treatment with anticho-
linesterase agents (such as Donepezil) have been excluded
from this study, due to the likely effect of these drugs on
the PFR. The necessary exclusion of those on anticholines-
terase agents introduces some bias as it is possible that
those not so treated are going to be different in some way
from the 60–70% of AD subjects who do receive such
therapy; for example, reported results from other studies
indicate that Donepezil may normalize PFR in some AD
patients [4, 5]. If PFR changes in AD relate to neurotrans-
mitter status, then PFR testing may be useful as an objec-
tive, noninvasive monitor with which to follow disease
progression and treatment efficacy.
As therapeutic trials in AD have shifted to earlier,
preclinical intervention [33, 34], the need has grown for a
practical screening test to identify those individuals on the
pathway to symptomatic AD. Clinicopathologic studies at
autopsy support the hypothesis of a protracted asymptomatic
stage of AD, with the slow buildup of Aβ protein plaques
beginning about 10–20 years prior to diagnosis [35–41].
PET Aβ neuroimaging provides a semiquantitative measure
of NAB [16, 18–20]. However, while it is a valuable
diagnostic and secondary screening biomarker, the proce-
dure is not suitable as a primary screening technology for
AD, due to cost, availability of PET scanners, invasiveness,
and radiation dose. There is consequently a need for a nonin-
vasive, cost-effective population-based AD screening tech-
nology to triage those requiring more extensive screening.
Recent results from Aβ immunotherapy trials have shown
promise, both for clearance of Aβ from the brain and
for slowing cognitive decline in early or preclinical AD
[33, 34], clearly underscoring the need for early detection.
To investigate pupillometry as a potential component of
such an AD screening test, the present study investigated
constriction phase pupil response in cognitively normal
healthy control individuals stratified according to PET-
determined NAB. The low-NAB group consists of cogni-
tively and neuropathologically normal healthy control
participants, while the high-NAB group consists of partici-
pants who have AD neuropathology but are still cognitively
normal, suggesting they are in the preclinical phase of AD.
Since the cross-sectional data suggest a weaker pupil
response in the high-NAB group, we hypothesized that longi-
tudinal monitoring of pupil response may perform better at
detecting preclinical AD. Natural variation in PFR between
individuals may limit the utility of a single PFR test for AD
screening; hence, it is possible that longitudinal monitoring
might facilitate more accurate preclinical detection or moni-
toring of AD. Hence, we also investigated longitudinal
changes in PFR over approximately 3 years. As the group
means for each PFR parameter change were negative, the
results suggested a decline in PFR over the period, consistent
with the observed age-dependence of PFR parameters in the
full cohort. The reduction in MCA was more pronounced in
the high-NAB group, with a similar trend for MCV (not
significant after multiple testing adjustment). Longitudinal
change in MCA and MCV provided good classification accu-
racy (AUC 0.9); hence, pupillometric changes over time may
have utility in detecting preclinical AD. The value of PFR
testing may be in its use for providing a noninvasive monitor
of physiological abnormality with which to follow disease
progression and treatment efficacy.
Overall, the results add to the evidence of a weaker pupil
flash response in AD and suggest that some PFR changes
may occur in preclinical AD. To our knowledge, we are the
only group to report on PFR differences with respect to
NAB and preclinical AD. Cholinergic depletion may occur
in preclinical AD, and pupillometry may have utility as a
component of a practical screening test for early detection
of AD. Additionally, longitudinal pupillometry could provide
a practical monitoring test for disease progression or
response to therapy.
The constriction phase of the PFR is primarily a para-
sympathetic response of the autonomic nervous system;
hence, constriction PFR parameters can be used as an accu-
rate method to assess the function of the neurotransmitter
involved, acetylcholine [1, 3, 42]. Studies have suggested that
PFR is sensitive to early cholinergic depletion which can lead
to a decline in cognitive function. Cholinergic depletion may
also occur in other diseases such as Parkinson’s disease [43],
which has also been reported to influence PFR [5, 9]. Hence,
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Figure 2: Comparison across clinical groups of the maximum
velocity in the constriction phase of the pupil flash response. HC
refers to healthy control participants, AD refers to Alzheimer’s
disease, mm refers to millimetres, and sec refers to seconds.
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the specificity of the PFR changes in AD needs further inves-
tigation using cohorts which include individuals with other
disorders that may affect the cholinergic system and PFR.
A major strength of this study is the well characterized
cohorts, including the presence of neuroimaging data that
enable deeper interrogation of associations between PFR
parameters and AD. A limitation was the small number
of participants (N = 27) in the longitudinal study; the
results warrant further investigation with a similarly well-
characterized, larger cohort.
5. Conclusions
This study demonstrates relationships between pupil
response parameters, neocortical amyloid plaque load, and
AD. Some PFR changes that are associated with diagnosed
AD also occur in preclinical AD.
Pupillometry demonstrates potential as an adjunct
(possibly together with blood or other biomarkers) (1) for
accurate diagnosis of AD and monitoring of disease progress
and response to therapy and (2) for low-cost and noninvasive
detection of preclinical AD, recruitment into preclinical
AD therapeutic trials and also monitoring response in
these trials.
The results of this study suggest that PFR monitoring,
rather than a single PFR test, might be more powerful as part
of an early screening test for AD and for monitoring disease
progress and response to intervention. Pupillometry is a
low-cost, noninvasive technology that may reflect early cho-
linergic deficits preceding memory and cognitive decline.
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